Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for screening H7N9 biomarkers in in-vitro blood plasma, and its application

A biomarker, plasma technology, applied in biological testing, biological material analysis, material testing products, etc., can solve unpublished reports, high mortality of severe H7N9 infection, and there is no biological predictor of disease severity and prognosis. Marker reporting and other issues to achieve excellent sensitivity and specificity

Active Publication Date: 2014-07-30
ZHEJIANG UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no biomarkers for predicting disease severity and prognosis have been reported
Mortality is high in severe H7N9 infection, and biomarkers to predict disease progression and prognosis in potentially lethal avian influenza infection are urgently needed but have not been published

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for screening H7N9 biomarkers in in-vitro blood plasma, and its application
  • Method for screening H7N9 biomarkers in in-vitro blood plasma, and its application
  • Method for screening H7N9 biomarkers in in-vitro blood plasma, and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0053] Specific schemes of the present invention are provided by the following examples:

[0054] Determination of plasma immune factors in H7N9 patients

[0055] (1) Experimental samples

[0056] 1. 46 H7N9 patients, 35 patients within 2 weeks of onset, and 80 plasma samples. The average age was 61 years, of which 22 were male.

[0057] 2. There were 21 H1N1 patients with an average age of 53.9 years, including 14 males.

[0058] 3. Six control samples were taken from healthy volunteers.

[0059] (2) Experimental materials

[0060] 1. Reagent Bio-Plex Pro Human Cytokine Array 27-Plex Group I, 21-Plex Group II, filter paper, 1ml pipette, 200ul pipette, 1ml sterile pipette tip, 200ul sterile pipette tip, 10ul sterile pipette tip 2, Instrument Luminex200, horizontal shaker, magnetic stand, 1.5ml EP tube, 2ml EP tube.

[0061] (3) Experimental steps

[0062] 1. Collection of cases

[0063] The diagnosis of H7N9 patients is based on the epidemiological contact history, clin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for screening H7N9 biomarkers in in-vitro blood plasma, and its application. The method comprises the following steps: 1, preparing blood plasma samples of H7N9 patients; 2, detecting the cytokine and the chemotactic factor of the blood plasma samples to obtain cytokine and chemotactic factor data; 3, comparing the cytokine and the chemotactic factor of H1N1 patients and healthy control blood plasma, and analyzing and processing the data to obtain H7N9 biomarkers; and 4, determining the mortality risk biomarker from the H7N9 biomarkers. An effective H7N9 immune molecular map is established by detecting and analyzing the cytokine and the chemotactic factor of the H7N9 patients from the point of the immune molecule, and the map is used for the in-vitro assessment of the mortality risk of the H7N9 patients. The method has better sensitivity and specificity than traditional detection methods.

Description

technical field [0001] The invention relates to the technical field of biological detection, in particular to new immune markers - plasma cytokines and chemokines of H7N9 patients, which can detect the risk of death of H7N9 patients in vitro. Background technique [0002] The human avian influenza virus has been found and identified as 17 H subtypes (H1~H17) and 10 H subtypes (H1~H17) and 10 subtypes according to the antigenicity of the outer membrane hemagglutinin (H) and neuraminidase (N) proteins of avian influenza A virus. N subtype (N1 ~ N10). The above-mentioned H subtype and N subtype are combined to form hundreds of avian influenza A viruses of different HxNx subtypes. Birds, especially waterfowl, are generally the natural hosts of these influenza viruses, and they mainly exist and spread in birds. [0003] Before 2013, the H7N9 subtype influenza virus was only found in poultry, and outbreaks among poultry had occurred in the Netherlands, Japan and the United States...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/53
CPCG01N33/54313G01N33/56983G01N2333/11
Inventor 李兰娟郭静陈瑜
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com